Gene therapy for X-linked SCID turned a childhood isolation chamber into ordinary life
Rhys Evans was born into a medical emergency. X-linked severe combined immunodeficiency left him without a functioning immune system, forcing his family into the brutal mathematics of infection control: sealed rooms, filtered air, sterilised visitors and the constant threat that an ordinary cold could become fatal. For much of his first year, life took place inside a protective “bubble,” a term that sounds abstract until it is used to describe a child cut off from the outside world.
The treatment that changed that trajectory was still experimental when he received it at Great Ormond Street Hospital 25 years ago. A new gene was inserted into his bone marrow, then the modified cells were returned to his body. His own marrow rebuilt an immune system carrying the repaired genetic instruction. Within weeks, his immune defences began to appear; shortly after his second birthday he developed flu and recovered, a real-world proof that the therapy had done what no conventional support could achieve.
A rare inherited disorder with early, often catastrophic consequences
SCID is not a single disease but a group of rare inherited disorders that cause major abnormalities of the immune system. Babies with the condition tend to develop infections more often than other infants, and those infections are usually more severe. Feeding difficulty, chronic diarrhoea, skin rashes and poor weight gain often follow, reflecting how completely the immune defect can disrupt early growth. Before modern treatment, most infants with SCID did not survive beyond their first birthday.
Great Ormond Street estimates that the condition affects about one in every 40,000 babies in England, or around 14 children a year. Even without UK-wide figures, the disease burden is clinically unmistakable: a newborn who should be building resilience instead remains exposed to pathogens that healthy infants would shrug off. The biology is unforgiving. When T-cell and broader immune function fail, the body loses the cellular machinery needed to control routine infections, let alone the kind of opportunistic illnesses that define severe immunodeficiency.
Evans’ early course fits that pattern. He lost weight, vomited, had diarrhoea and twice developed pneumonia. His family was offered only difficult alternatives at the time: chemotherapy or a bone marrow transplant, both serious interventions in a child whose immune system was already severely compromised. The decision to proceed with gene therapy meant accepting an approach that had been developed in the laboratory over 15 to 20 years and was ready only because researchers believed the preclinical evidence justified human use.
How the first treatment worked in practice
The procedure was disarmingly simple in description and far from simple in meaning. Doctors collected 100 ml of Evans’ bone marrow, inserted the therapeutic gene, then infused the treated marrow back into his body. No additional intervention followed at that point. The strategy relied on the body’s own hematopoietic machinery to repopulate the immune system with corrected cells, allowing the marrow to do the repair work itself.
That is the central advantage of gene therapy in inherited immune disorders: it tries to replace a broken instruction set at its source rather than chase each infection after it appears. By correcting stem cells in the bone marrow, the treatment can generate a lasting supply of immune cells with functional genetic programming. In a disorder where the defect is present from birth, the appeal is obvious. The challenge has always been safety, durability and the ability to translate a laboratory success into a stable clinical outcome in children who cannot wait for incremental progress.
Evans became the first patient in that programme. His case was, in the plainest sense, a test of whether a repaired genome could translate into a live, functioning immune system. The answer arrived not in a laboratory readout but in daily life: fewer medical restrictions, the ability to go to school and university, and the capacity to plan for a future his family once could not assume.
More than 130 patients have followed him through the same pathway
Adrian Thrasher, who pioneered the therapy with colleagues from University College London and Great Ormond Street, said more than 130 people have received the treatment since 2001. The first case was not just a milestone; it opened the door to a broader clinical programme in which gene therapy moved from concept to repeated practice. Most of the children treated in the hospital’s gene therapy trials have had different forms of SCID, although the programme has also included patients with leukaemia, spinal muscular atrophy and Leber’s congenital amaurosis.
That breadth matters because it shows how the same underlying technology can address different genetic disorders when the molecular target is clear enough. In SCID, the target is immediate and intuitive: restore immune function before infection claims the child. In other inherited diseases, the therapeutic logic changes, but the principle remains the same — correct the pathogenic gene and let the body resume a function it could not perform on its own.
The aftermath in Evans’ life is almost startling in its ordinariness. He now works as stage crew at Butlin’s in Minehead, Somerset. He has beaten Covid twice and believes he can now fight most viruses. Weekly antibiotic infusion remains one lingering reminder of his early medical history, along with warts on his hands. Otherwise, the illness that once confined him is largely absent from daily life.
A treatment once framed as a last resort is now part of clinical reality
Thrasher recently met Evans again at Great Ormond Street and described the outcome as deeply gratifying. He also stressed the ethical weight of the original decision. The therapy was not presented to the family as a sales pitch, but as one option among several in an exceptionally difficult situation. Explaining gene therapy to parents of a seriously ill child is never straightforward, especially when the treatment involves altering bone marrow cells with a new gene and then waiting for the body to prove the idea correct.
Evans sees the result from the other side of the bedrail. He describes himself as the “guinea pig” whose treatment helped make later care possible, and his gratitude is rooted in the fact that the therapy not only saved him but also helped define a path for others. The earliest patients in any advanced genetic programme carry that burden and that privilege at once: they accept uncertainty so future children can benefit from a therapy backed by real-world experience rather than theory alone.
The story closes on a practical clinical note. Gene therapy did not simply buy Rhys Evans more time; it replaced a lethal immune defect with enough immune function to let him live without a bubble. The remaining questions belong to the broader field: how best to expand access, how long these corrected cells remain durable across a lifetime, and which other inherited disorders can be treated with the same precision without compromising safety.